Wesley R. Zemrak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wesley R. Zemrak has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Kathryn E. Smith
Department of Pharmacy, Maine Medical Center, Portland, ME, 04105, USA
3 shared publications- David B. Seder
Maine Med Ctr, Dept Crit Care Serv, Portland, ME 04102 USA
2 shared publications - Robert L. Trowbridge
Department of Medicine, Maine Medical Center, Portland, ME, USA
2 shared publications Amber R. Rollins
VA Connecticut Healthcare System, West Haven, CT, USA
1 shared publicationBrian Carlone
Department of Pharmacy, Maine Medical Center, Portland, ME, 04105, USA
1 shared publicationCasey Z. MacVane
Department of Emergency Medicine, Maine Medical Center, 22 Bramhall St, Portland, ME, 04102, United States
1 shared publication
Latest Publications
- Open Access
- 1 July 2021
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 11 (4) , 254-258
Safety of ECT in patients receiving an oral anticoagulant
Introduction: This study assessed the use, tolerability, and safety of anticoagulation via direct oral anticoagulants or warfarin in medical and psychiatric inpatients receiving ECT. Methods: This retrospective cohort study included 32 patients who received ECT while on either a direct oral anticoagulant (9) or warfarin (23) and spanned 247 encounters at Maine Medical Center between December 2012 and December 2018. Data are presented descriptively and analyzed using SPSS version 25 and Microsoft Excel version 2016. Results: Among the 247 ECT patient encounters, there were few major adverse effects of ECT in this medically complex population. These adverse effects included headache during 4 encounters (1.6%), respiratory distress during 2 encounters (0.8%) and a cardiovascular event during 1 encounter (0.4%). One patient (3.1%) who was receiving concurrent rivaroxaban and venlafaxine experienced gastrointestinal bleeding that was determined to be unrelated to ECT. One patient on fluoxetine and warfarin experienced hemoptysis thought to be secondary to epistaxis. No other major bleeding or clotting event occurred during an ECT session nor for the duration of the hospitalization. Discussion: Direct oral anticoagulants and warfarin appear safe in the treatment of patients with atrial fibrillation or acute venous thromboembolism who are receiving concomitant ECT. Prospective studies are needed to confirm these findings.
- 1 July 2021
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 11 (4) , 254-258
Open AccessSafety of ECT in patients receiving an oral anticoagulant
Introduction: This study assessed the use, tolerability, and safety of anticoagulation via direct oral anticoagulants or warfarin in medical and psychiatric inpatients receiving ECT. Methods: This retrospective cohort study included 32 patients who received ECT while on either a direct oral anticoagulant (9) or warfarin (23) and spanned 247 encounters at Maine Medical Center between December 2012 and December 2018. Data are presented descriptively and analyzed using SPSS version 25 and Microsoft Excel version 2016. Results: Among the 247 ECT patient encounters, there were few major adverse effects of ECT in this medically complex population. These adverse effects included headache during 4 encounters (1.6%), respiratory distress during 2 encounters (0.8%) and a cardiovascular event during 1 encounter (0.4%). One patient (3.1%) who was receiving concurrent rivaroxaban and venlafaxine experienced gastrointestinal bleeding that was determined to be unrelated to ECT. One patient on fluoxetine and warfarin experienced hemoptysis thought to be secondary to epistaxis. No other major bleeding or clotting event occurred during an ECT session nor for the duration of the hospitalization. Discussion: Direct oral anticoagulants and warfarin appear safe in the treatment of patients with atrial fibrillation or acute venous thromboembolism who are receiving concomitant ECT. Prospective studies are needed to confirm these findings.
- Open Access
- 20 May 2020
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 4 (5) , 936-941
Heparin‐induced thrombocytopenia with thrombosis in COVID‐19 adult respiratory distress syndrome
- 20 May 2020
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 4 (5) , 936-941
Open AccessHeparin‐induced thrombocytopenia with thrombosis in COVID‐19 adult respiratory distress syndrome
- 15 November 2018
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 47 (2) , 263-271
Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal
Four-factor PCC is the recommended standard of care for acute warfarin reversal but optimal dosing is unknown. We aim to show that a low-dose strategy is often adequate and may reduce the risk of thromboembolic events when compared to manufacturer-recommended dosing.
- 15 November 2018
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 47 (2) , 263-271
Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal
Four-factor PCC is the recommended standard of care for acute warfarin reversal but optimal dosing is unknown. We aim to show that a low-dose strategy is often adequate and may reduce the risk of thromboembolic events when compared to manufacturer-recommended dosing.
- 28 June 2017
- Published by Springer Nature in Neurocritical Care
- Vol. 27 (3) , 334-340
Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0
Prothrombin complex concentrates (PCCs) have become the first-line therapy for warfarin reversal in the setting of central nervous system (CNS) hemorrhage. Randomized, controlled studies comparing agents for warfarin reversal excluded patients with international normalized ratio (INR) <2, yet INR values of 1.6–1.9 are also associated with poor outcomes.
- 28 June 2017
- Published by Springer Nature in Neurocritical Care
- Vol. 27 (3) , 334-340
Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0
Prothrombin complex concentrates (PCCs) have become the first-line therapy for warfarin reversal in the setting of central nervous system (CNS) hemorrhage. Randomized, controlled studies comparing agents for warfarin reversal excluded patients with international normalized ratio (INR) <2, yet INR values of 1.6–1.9 are also associated with poor outcomes.
- 1 October 2016
- Published by Elsevier in The Lancet Neurology
- Vol. 15 (11) , 1116-7
Haematoma expansion and vitamin K antagonist reversal.
- 1 October 2016
- Published by Elsevier in The Lancet Neurology
- Vol. 15 (11) , 1116-7
Haematoma expansion and vitamin K antagonist reversal.
- 5 August 2016
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 50 (12) , 1001-1008
Implementation of a Simplistic Bivalirudin-Warfarin Transition Protocol Is Associated With Improved Achievement of INR Values Within the Therapeutic Range
Background: Transition from bivalirudin to long-term warfarin therapy is often difficult to execute due to bivalirudin prolongation of the international normalized ratio (INR), and literature to help guide this transition is extremely limited. Objective: To assess the transition from bivalirudin to warfarin after implementation of an institution-wide transition protocol. Methods: In this retrospective quasiexperimental study, adult patients receiving bivalirudin directly followed by warfarin for nonprocedural systemic anticoagulation were evaluated to determine the frequency of successful transition to warfarin. Participants were compared before (preprotocol) and after (postprotocol) the implementation of the transition protocol. Results: A total of 39 patients met inclusion criteria and were included in the analysis (preprotocol = 19; postprotocol = 20). The percentage of patients achieving a successful transition was significantly higher in the postprotocol group compared with the preprotocol group (80.0% vs 42.1%, P = 0.015). Bleeding events were similar between the 2 groups (23.1% vs 16.7%, P = 0.689). Withholding of warfarin doses or the use of anticoagulant reversal agents or blood transfusions for supratherapeutic INR levels, surgical procedures, or drop in hemoglobin was numerically lower in the postprotocol group compared with the preprotocol group (16.7% vs 46.2%, P = 0.202). Conclusion: Implementation of a simplistic bivalirudin-warfarin transition protocol significantly increased the frequency of therapeutic INR results on bivalirudin discontinuation. Additionally, patients treated according to this protocol were less likely to have warfarin doses withheld or require reversal agents. Larger studies testing this transition strategy are warranted.
- 5 August 2016
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 50 (12) , 1001-1008
Implementation of a Simplistic Bivalirudin-Warfarin Transition Protocol Is Associated With Improved Achievement of INR Values Within the Therapeutic Range
Background: Transition from bivalirudin to long-term warfarin therapy is often difficult to execute due to bivalirudin prolongation of the international normalized ratio (INR), and literature to help guide this transition is extremely limited. Objective: To assess the transition from bivalirudin to warfarin after implementation of an institution-wide transition protocol. Methods: In this retrospective quasiexperimental study, adult patients receiving bivalirudin directly followed by warfarin for nonprocedural systemic anticoagulation were evaluated to determine the frequency of successful transition to warfarin. Participants were compared before (preprotocol) and after (postprotocol) the implementation of the transition protocol. Results: A total of 39 patients met inclusion criteria and were included in the analysis (preprotocol = 19; postprotocol = 20). The percentage of patients achieving a successful transition was significantly higher in the postprotocol group compared with the preprotocol group (80.0% vs 42.1%, P = 0.015). Bleeding events were similar between the 2 groups (23.1% vs 16.7%, P = 0.689). Withholding of warfarin doses or the use of anticoagulant reversal agents or blood transfusions for supratherapeutic INR levels, surgical procedures, or drop in hemoglobin was numerically lower in the postprotocol group compared with the preprotocol group (16.7% vs 46.2%, P = 0.202). Conclusion: Implementation of a simplistic bivalirudin-warfarin transition protocol significantly increased the frequency of therapeutic INR results on bivalirudin discontinuation. Additionally, patients treated according to this protocol were less likely to have warfarin doses withheld or require reversal agents. Larger studies testing this transition strategy are warranted.
- 1 August 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (8) , 1736.e1-1736.e3
Thrombotic complications following the administration of high-dose prothrombin complex concentrate for acute warfarin reversal
- 1 August 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (8) , 1736.e1-1736.e3
Thrombotic complications following the administration of high-dose prothrombin complex concentrate for acute warfarin reversal